These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 30878319)

  • 21. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
    McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.
    Horan JT; Liesveld JL; Fenton P; Blumberg N; Walters MC
    Bone Marrow Transplant; 2005 Jan; 35(2):171-7. PubMed ID: 15531901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes.
    Klein OR; Bapty S; Lederman HM; Younger MEM; Zambidis ET; Jones RJ; Cooke KR; Symons HJ
    J Clin Immunol; 2021 Feb; 41(2):414-426. PubMed ID: 33159275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation.
    Dimitrov M; Merkle S; Cao Q; Tryon RK; Vercellotti GM; Holtan SG; Kao RL; Srikanthan M; Terezakis SA; Tolar J; Ebens CL
    Transplant Cell Ther; 2024 Oct; 30(10):1005.e1-1005.e17. PubMed ID: 39002862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
    Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
    Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.
    Ghosh N; Ye X; Tsai HL; Bolaños-Meade J; Fuchs EJ; Luznik L; Swinnen LJ; Gladstone DE; Ambinder RF; Varadhan R; Shanbhag S; Brodsky RA; Borrello IM; Jones RJ; Matsui W; Huff CA
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1903-1909. PubMed ID: 28711728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.
    Kasamon YL; Fuchs EJ; Zahurak M; Rosner GL; Symons HJ; Gladstone DE; Huff CA; Swinnen LJ; Brodsky RA; Matsui WH; Borrello I; Shanbhag S; Cooke KR; Ambinder RF; Luznik L; Bolaños-Meade J; Jones RJ
    Biol Blood Marrow Transplant; 2018 May; 24(5):1022-1028. PubMed ID: 29353109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms.
    Monaco F; Scott BL; Chauncey TR; Petersen FB; Storer BE; Baron F; Flowers ME; Deeg HJ; Maloney DG; Storb R; Sandmaier BM
    Haematologica; 2019 Jun; 104(6):1221-1229. PubMed ID: 30630975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation.
    Fernandes JF; Bonfim C; Kerbauy FR; Rodrigues M; Esteves I; Silva NH; Azambuja AP; Mantovani LF; Kutner JM; Loth G; Kuwahara CC; Bueno C; Kondo AT; Ribeiro AAF; Kok F; Hamerschlak N
    Bone Marrow Transplant; 2018 Apr; 53(4):392-399. PubMed ID: 29330393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
    Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
    Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases.
    Sarina B; Mancosu P; Navarria P; Bramanti S; Mariotti J; De Philippis C; Clerici E; Franzese C; Mannina D; Valli V; Carlo-Stella C; Scorsetti M; Santoro A; Castagna L
    Transplant Cell Ther; 2021 Jun; 27(6):492.e1-492.e6. PubMed ID: 33857448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
    Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Children and Adolescents with Fanconi Anemia.
    Bonfim C; Ribeiro L; Nichele S; Loth G; Bitencourt M; Koliski A; Kuwahara C; Fabro AL; Pereira NF; Pilonetto D; Thakar M; Kiem HP; Page K; Fuchs EJ; Eapen M; Pasquini R
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):310-317. PubMed ID: 27832981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haploidentical bone marrow transplants for haematological malignancies using non-myeloablative conditioning therapy and post-transplant immunosuppression with cyclophosphamide: results from a single Australian centre.
    Bilmon IA; Kwan J; Gottlieb D; Kerridge I; McGurgan M; Huang G; George B; Hertzberg M; Bradstock KF
    Intern Med J; 2013 Feb; 43(2):191-6. PubMed ID: 22646924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
    Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.
    McCurdy SR; Kanakry CG; Tsai HL; Kasamon YL; Showel MM; Bolaños-Meade J; Huff CA; Borrello I; Matsui WH; Brodsky RA; Ambinder RF; Bettinotti MP; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):343-352. PubMed ID: 29055682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
    Choi SW; Braun T; Chang L; Ferrara JL; Pawarode A; Magenau JM; Hou G; Beumer JH; Levine JE; Goldstein S; Couriel DR; Stockerl-Goldstein K; Krijanovski OI; Kitko C; Yanik GA; Lehmann MH; Tawara I; Sun Y; Paczesny S; Mapara MY; Dinarello CA; DiPersio JF; Reddy P
    Lancet Oncol; 2014 Jan; 15(1):87-95. PubMed ID: 24295572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Failure to Prevent Severe Graft-Versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Chronic Granulomatous Disease.
    Parta M; Hilligoss D; Kelly C; Kwatemaa N; Theobald N; Zerbe CS; Holland SM; Malech HL; Kang EM
    J Clin Immunol; 2020 May; 40(4):619-624. PubMed ID: 32314173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.